Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome

Cancer Research

Volumn 64, Issue 23, 2004, Pages 8767-8772

  Berger, Aaron J ^a   Camp, Robert L ^a   DiVito, Kyle A ^a   Kluger, Harriet M ^a   Halaban, Ruth ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN HOMOLOGUE OF MURINE DOUBLE MINUTE 2 PROTEIN; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOMATED QUANTITATIVE ANALYSIS; BIOASSAY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; MELANOMA; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSESSMENT OF PROTEIN EXPRESSION; SKIN BIOPSY; SKIN CANCER; VALIDATION PROCESS;

CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 9244241036     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1384     Document Type: Article

References (43)

1. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 1996;34:839-47.
2. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2001. Vol. 2004. Bethesda, MD: National Cancer Institute; 2004.
3. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA - Cancer J Clin 2003;53:5-26.
4. Weinstock MA. Do sunscreens increase or decrease melanoma risk: an epidemiologic evaluation. J Investig Dermatol Symp Proc 1999;4:97-100.
5. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA - Cancer J Clin 2002;52:23-47.
6. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (Lond.) 2000;406:536-40.
7. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
8. Clark WH Jr, Ainsworth AM, Bernardino EA, et al. The developmental biology of primary human malignant melanomas. Semin Oncol 1975;2:83-103.
9. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
10. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004;164:193-203.
11. Korabiowska M, Bauer H, Quentin T, et al. Application of new in situ hybridization probes for Ku70 and Ku80 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemical analysis. Hum Pathol 2004;35:210-6.
12. Taylor CR. The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med 2000;124:945-51.
13. Thomson TA, Hayes MM, Spinelli JJ, et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001;14:1079-86.
14. Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol (Lond.) 1994;47:816-22.
15. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
16. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-7.
17. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63:1445-8.
18. Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative determination of expression of the prostate alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004;164:831-40.
19. Smoller BR. Immunohistochemistry in the diagnosis of melanocytic neoplasms. Pathology (Phila.) 1994;2:371-83.
20. Dabbs DJ. Diagnostic immunohistochemistry. 1st ed. Philadelphia: Churchill Livingstone; 2002.
21. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature (Lond.) 2000;408:307-10.
22. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58.
23. Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene 1997;15:1001-10.
24. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004;2:1-8.
25. Hernberg M, Turunen JP, von Boguslawsky K, Muhonen T, Pyrhonen S. Prognostic value of biomarkers in malignant melanoma. Melanoma Res 1998;8:283-91.
26. 1-S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000;28:404-14.
27. Polsky D, Melzer K, Hazan C, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst (Bethesda) 2002;94:1803-6.
28. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003;63:8103-7.
29. Rimm DL, Camp RL, Charette LA, et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7:24-31.
30. Matsumura T, Yoshihama Y, Kimura T, Shintani S, Alcalde RE. p53 and MDM2 expression in oral squamous cell carcinoma. Oncology 1996;53:308-12.
31. Pilotti S, Della Torre G, Lavarino C, et al. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol 1997;181:14-24.
32. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 1997;75:1302-8.
33. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Investig 2000;80:1943-9.
34. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249-56.
35. Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 2004;36:147-50.
36. Ganguli G, Wasylyk B. p53-independent functions of MDM2. Mol Cancer Res 2003;1:1027-35.
37. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003;1:993-1000.
38. Moll UM, Zaika A. Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 2001;493:65-9.
39. Ferbeyre G, de Stanchina E, Lin AW, et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002;22:3497-508.
40. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
41. Olsen CL, Gardie B, Yaswen P, Stampfer MR. Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion. Oncogene 2002;21:6328-39.
42. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996;15:6979-90.
43. Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 2003;1:1009-16.